03:54:07 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Shell Summary for Oct. 6, 2015

2015-10-06 21:00 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange added 8.78 points to 538.69 Tuesday. William Galane's Canadian Securities Exchange shell, Expedition Mining Inc. (EXU), plans to complete a reverse takeover of BSS Life Sciences Inc., a medical imaging business with a product that the company hopes will improve the ability of doctors to detect cancer.

The shell, which has 3,889,113 shares outstanding, will issue 26.5 million shares to the shareholders of BSS, five million of which will be held in escrow, to be released when certain conditions are met. Dr. Stavros Demos is a physicist and research scientist at Lawrence Livermore National Laboratory, a U.S. government lab in Livermore, Calif., where he invented BSS's technology. The company will continue using the laboratory in Livermore for clinical evaluations that will hopefully support BSS's 510(k) FDA submission.

The first application of the technology is an endoscopy imaging system for detecting bladder cancer. For anyone unfamiliar with scientific terms, endoscopy simply means "looking inside." As such, an endoscope is a medical device with an attached light used to find suspicious masses in the hollow organs of the body, including the esophagus, lungs and urinary tract. According to BSS, conventional endoscopes rely on white light to illuminate tissues for doctors when they are looking for these suspicious masses, but white light is limiting. Some companies use blue light in conjunction with imaging agents or chemical dyes to catch cancers that may have been missed using only white light, but those dyes can cause various adverse effects including anaphylaxis shock. BSS is working on using white light and other wavelengths of light, ones that require a fraction of the chemical dyes or none at all, to spot cancers.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2024 Canjex Publishing Ltd. All rights reserved.


Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.


Comments for this item are closed